Skip to content

PP&E Sale Proceeds at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$0-100%
Enliven Therapeutics logo
Enliven TherapeuticsELVN
$53.25K

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$693.87M+192%
Enterprise value$501.88M+220%
P/S5,595.7×-18,674×

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Candel Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s pp&e sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s PP&E sale proceeds?
Candel Therapeutics, Inc. (CADL) reported PP&E sale proceeds of $6.75K in Q4 2025.
What does PP&E sale proceeds mean?
Cash received from selling property, plant, and equipment no longer needed for operations.